Nothing seems to bother NASDAQ:PDD, NASDAQ:MLVF, NASDAQ:ALDX, NASDAQ:ACHV

PINDUODUO EARNINGS ESTIMATES AND ACTUALS BY QUARTER (NASDAQ:PDD)

IS PINDUODUO A BUY RIGHT NOW? (NASDAQ:PDD)

19 Wall Street research analysts have issued “buy,” “hold,” and “sell” ratings for Pinduoduo in the last year. There are currently 5 hold ratings and 14 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should “buy” Pinduoduo stock.
Pinduoduo

MALVERN BANCORP (NASDAQ:MLVF) EARNINGS INFORMATION (NASDAQ:MLVF)

Malvern Bancorp last issued its earnings results on March 9th, 2021. The savings and loans company reported $0.30 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.25 by $0.05. Malvern Bancorp has generated $0.84 earnings per share over the last year and currently has a price-to-earnings ratio of 18.1. Malvern Bancorp has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Wednesday, May 5th, 2021 based off prior year’s report dates.

IS MALVERN BANCORP A BUY RIGHT NOW? (NASDAQ:MLVF)

1 Wall Street analysts have issued “buy,” “hold,” and “sell” ratings for Malvern Bancorp in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street analysts is that investors should “hold” Malvern Bancorp stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MLVF, but not buy additional shares or sell existing shares.
Malvern Bancorp

ALDEYRA THERAPEUTICS (NASDAQ:ALDX) EARNINGS INFORMATION (NASDAQ:ALDX)

Aldeyra Therapeutics last posted its earnings data on March 10th, 2021. The biotechnology company reported ($0.30) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.28) by $0.02. Aldeyra Therapeutics has generated ($2.05) earnings per share over the last year. Aldeyra Therapeutics has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Thursday, May 6th, 2021 based off prior year’s report dates.

IS ALDEYRA THERAPEUTICS A BUY RIGHT NOW? (NASDAQ:ALDX)

11 Wall Street analysts have issued “buy,” “hold,” and “sell” ratings for Aldeyra Therapeutics in the last twelve months. There are currently 1 hold rating and 10 buy ratings for the stock. The consensus among Wall Street analysts is that investors should “buy” Aldeyra Therapeutics stock.
Aldeyra Therapeutics

ACHIEVE LIFE SCIENCES (NASDAQ:ACHV) EARNINGS INFORMATION (NASDAQ:ACHV)

Achieve Life Sciences last posted its quarterly earnings data on March 11th, 2021. The biopharmaceutical company reported ($1.11) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.27) by $0.16. Achieve Life Sciences has generated ($39.80) earnings per share over the last year. Achieve Life Sciences has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Thursday, May 13th, 2021 based off prior year’s report dates.

IS ACHIEVE LIFE SCIENCES A BUY RIGHT NOW? (NASDAQ:ACHV)

3 Wall Street research analysts have issued “buy,” “hold,” and “sell” ratings for Achieve Life Sciences in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should “buy” Achieve Life Sciences stock.
Achieve Life Sciences